Loading…
Telix Pharmaceuticals Limited is projected to rise to $12.64 by 2027, a +26% move from its current price of $10.06. TLX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $9.83 | $10.06 | $10.31 | +0.03% |
| Aug 2 | $9.73 | $10.07 | $10.41 | +0.07% |
| Aug 3 | $9.66 | $10.07 | $10.50 | +0.10% |
| Aug 4 | $9.60 | $10.07 | $10.57 | +0.14% |
| Aug 5 | $9.55 | $10.08 | $10.63 | +0.17% |
| Aug 6 | $9.51 | $10.08 | $10.69 | +0.20% |
| Aug 7 | $9.47 | $10.08 | $10.74 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.47 | $10.08 | $10.74 | +0.24% |
| Week 2 | $9.24 | $10.11 | $11.06 | +0.48% |
| Week 3 | $9.08 | $10.13 | $11.31 | +0.72% |
| Week 4 | $8.95 | $10.16 | $11.53 | +0.95% |
| Week 5 | $8.84 | $10.18 | $11.73 | +1.19% |
| Week 6 | $8.74 | $10.20 | $11.92 | +1.44% |
| Week 7 | $8.65 | $10.23 | $12.09 | +1.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. It operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, TLX252, TLX400, TLX102, TLX300, and TLX090 across various oncology targets, as well as BiPASS in Phase 3 for prostate cancer diagnosis, AlFluor, TLX250-Px, and TLX101-Px. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally and has a strategic collaboration with University Hospital Essen.
The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLX is Telix Pharmaceuticals Limited (TLX), a Healthcare stock with current price $10.32 and a market cap of $3.5B, ranking 1587 by market cap. This places it among mid-sized healthcare peers with a global operating footprint.
The price outlook provided shows a multi-year forecast with rising average prices and meaningful upside from 2027 onward. The 2026 forecast sets a base with an average of $10.32 and a range of $6.41 to $14.38, described with a 0% ROI and NEUTRAL sentiment.
From 2027 onward, the average price climbs to $13.28, $14.14 in 2028, $14.91 in 2029, and $17.79 in 2030, with bullish sentiment and rising ROI (28.7% in 2027, 37% in 2028, 44.5% in 2029, and 72.4% in 2030).
The forecast continues to show substantial upside through 2040 and into 2050, with 2040 average $46.95 and max $78.94 (ROI 354.9) and 2050 average $107.19 with max $197.05 (ROI 938.7). These figures illustrate a long-run bullish trajectory, though they are estimates and not guarantees.
A major floor 15.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.2% away) — a key level to hold.
The nearest ceiling, 20.8% above — a clean break opens room to run.
A major ceiling 28.5% above — clearing it would confirm fresh momentum.
Key TLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.11 | Sell | $10.16 | Sell |
| MA 10 | $10.33 | Sell | $10.35 | Sell |
| MA 20 | $10.88 | Sell | $10.54 | Sell |
| MA 50 | $10.32 | Sell | $10.43 | Sell |
| MA 100 | $10.05 | Buy | $10.08 | Sell |
| MA 200 | $9.30 | Buy | $10.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.23 | Neutral |
| Stoch RSI (14) | 10.34 | Buy |
| CCI (20) | -97.24 | Neutral |
| Williams %R (14) | -93.89 | Info |
| MACD (12,26,9) | -0.14 | Sell |
| ROC (12) | -8.71 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 6.11 | Buy |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | -0.57 | Sell |
| Ultimate (7,14,28) | 30.68 | Neutral |
| Momentum (10) | -0.77 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 9.98 | Buy |
| ADX (14) | 16.63 | Neutral |
| ATR (14) | 0.25 | Info |
The near-term technical picture remains bullish despite a modest RSI of 40, with the stock trading around the $10 area. The 50-day simple moving average sits at $10.36, slightly above the current price, while the 200-day average stands at $9.30, signaling a longer-term uptrend.
Key support sits at $9.41 and resistance at $12.15. The 30-day price range spans from $8.64 to $12.32, offering a channel within which the stock could move in the near term. Overall, sentiment is bullish, suggesting potential for a move toward the resistance level if buyer momentum strengthens.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.41 | $10.06 | $13.57 | 0% | Neutral | |
| $10.19 | $12.64 | $16.50 | +26% | Bullish | |
| $10.47 | $13.30 | $17.95 | +32% | Bullish | |
| $10.57 | $13.70 | $18.99 | +36% | Bullish | |
| $12.19 | $16.09 | $22.79 | +60% | Bullish | |
| $13.72 | $18.39 | $26.56 | +83% | Bullish | |
| $15.59 | $21.22 | $31.18 | +111% | Bullish | |
| $17.50 | $24.15 | $36.03 | +140% | Bullish | |
| $17.40 | $24.34 | $36.85 | +142% | Bullish | |
| $18.29 | $25.90 | $39.74 | +157% | Bullish | |
| $26.01 | $38.97 | $63.26 | +287% | Bullish | |
| $50.26 | $82.90 | $146.15 | +724% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.41 | $10.06 | $11.72 | +0.00% |
| August 2026 | $8.57 | $10.03 | $12.00 | -0.26% |
| September 2026 | $8.80 | $10.38 | $12.56 | +3.41% |
| October 2026 | $8.91 | $10.57 | $12.91 | +1.84% |
| November 2026 | $8.88 | $10.58 | $13.02 | +0.14% |
| December 2026 | $9.14 | $10.95 | $13.57 | +3.46% |
Click any year to see its month-by-month TLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TLX is projected to trade between $6.41 and $13.57, averaging $10.06 — a potential gain of 0% from today's $10.06. A consolidation phase looks the most probable path here.
Telix Pharmaceuticals Limited's 2027 outlook centres on $12.64, within a $10.19 to $16.50 range. That is up +26% on the projected 2026 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2028, TLX could reach as high as $17.95, with a base case around $13.30 and support toward $10.47 — roughly +32% from $10.06. Buyers look set to stay in control over this stretch.
Expect TLX to range from $10.57 to $18.99 through 2029. The $13.70 average target implies a +36% move from current prices. That is up +3% on the projected 2028 average. Momentum favours further upside here.
The TLX price prediction for 2030 points to an average of $16.09 (low $12.19, high $22.79) — a potential gain of +60% on today's $10.06. Buyers look set to stay in control over this stretch.
In 2031, TLX is projected to trade between $13.72 and $26.56, averaging $18.39 — a potential gain of +83% from today's $10.06. That is up +14% on the projected 2030 average. Momentum favours further upside here.
Telix Pharmaceuticals Limited's 2032 outlook centres on $21.22, within a $15.59 to $31.18 range. That is up +15% on the projected 2031 average. That marks a +111% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TLX could reach as high as $36.03, with a base case around $24.15 and support toward $17.50 — roughly +140% from $10.06. Momentum favours further upside here.
Expect TLX to range from $17.40 to $36.85 through 2034. The $24.34 average target implies a +142% move from current prices. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TLX price prediction for 2035 points to an average of $25.90 (low $18.29, high $39.74) — a potential gain of +157% on today's $10.06. Momentum favours further upside here.
In 2040, TLX is projected to trade between $26.01 and $63.26, averaging $38.97 — a potential gain of +287% from today's $10.06. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Telix Pharmaceuticals Limited's 2050 outlook centres on $82.90, within a $50.26 to $146.15 range. That is up +113% on the projected 2040 average. That marks a +724% change versus current levels. Momentum favours further upside here.
Investing $1,000 in TLX today (≈ 99.403579 TLX) could be worth
$8,240.57
+$7,240.57 (+724%) by 2050 · US Dollar
Based on the average projected TLX price of $82.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TLXwould be worth at today's price.
$1,000 invested in TLX on Jul 30, 2025 (≈ 74.074074 TLX) would be worth
$745.19
-$254.81 (-25.5%) today · 0.75× · US Dollar
Based on a TLX entry price of $13.5 vs. today's $10.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.51 | $957.18 | -4.3% |
| 1 month ago | $11.53 | $872.51 | -12.7% |
| 3 months ago | $11.26 | $893.43 | -10.7% |
| 6 months ago | $7.28 | $1,381.87 | +38.2% |
| 1 year ago | $13.5 | $745.19 | -25.5% |
| All time (1.7y) ago | $15.15 | $664.03 | -33.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TLX forecast.
Our base-case forecast reaches $20.00 around 2032.
Implied market cap at $20.00: $6.78B
Longer-horizon forecasts point to a strong path of appreciation, with the average price rising from $10.32 in 2026 to $107.19 by 2050. The forecast shows a move through 2027 at $13.28, 2028 at $14.14, 2029 at $14.91, and 2030 at $17.79, accompanied by growing upside potential (ROI from 28.7% in 2027 to 72.4% in 2030).
Beyond 2030, the trajectory remains bullish, with 2040 expected to average $46.95 and 2050 $107.19, while max values rise to $78.94 in 2040 and $197.05 in 2050. The outlook indicates improving sentiment and meaningful upside over the long run, but as with all forecasts these are estimates and not guarantees. Investors should consider the range of outcomes and inherent uncertainties in such projections.
Tap a question to reveal the answer.
The forecast shows the average price in 2030 is $17.79, with a min of $13.23 and a max of $25.78, and a ROI of 72.4%, with bullish sentiment.
The forecast indicates a bullish sentiment from 2027 onward, with rising average prices (e.g., $13.28 in 2027, $14.14 in 2028, $14.91 in 2029, $17.79 in 2030) and positive ROIs (28.7% in 2027, 37% in 2028, 44.5% in 2029, 72.4% in 2030). These are estimates and not guarantees.
The 2050 forecast max is $197.05, so the model’s stated ceiling is just below $200.
$8.64 to $12.32.
Telix Pharmaceuticals Limited Community Discussion
0Share your Telix Pharmaceuticals Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.